Michael J Pishvaian
Johns Hopkins Kimmel Cancer Center · Georgetown University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael J Pishvaian as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:44 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT03257033 · Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPCRenovoRx · active not recruiting · Locally Advanced Pancreatic Cancer · study chair
- Ph1NCT02444793 · A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid TumorsPfizer · terminated · Advanced/Metastatic Solid Tumors · principal investigator
- Ph1NCT01050985 · A Study of Temsirolimus Plus Capecitabine in Patients With Advanced CancerGeorgetown University · completed · Advanced Solid Tumors · principal investigator
- Ph2NCT01051596 · A Study of ABT-888 in Combination With Temozolomide for Colorectal CancerGeorgetown University · completed · Colorectal Cancer · principal investigator
- Ph1NCT01051284 · A Study of Gemcitabine and Cyberknife Radiation Therapy for Pancreatic CancerGeorgetown University · completed · Pancreatic Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:44 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Clinical Protocol and Data ManagementP30CA051008 · NCI · GEORGETOWN UNIVERSITY · fiscal years 2019 to 2022 · $134,315 awarded in 2022Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name in pancreatic cancer, ranked by citations from NIH iCite, fetched 2026-11-12 12:44 UTC. The ranking covers the 200 most relevant of 9 PubMed records, and a shared surname and initials can bring in a namesake. All 9 on PubMed
- 127 citationsRCR 5.8
- Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.Radiat Oncol · 201390 citationsRCR 2.9
- A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer.Clin Cancer Res · 202039 citationsRCR 1.5
- 39 citationsRCR 7.3
- Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer.Cancer Chemother Pharmacol · 201537 citationsRCR 1.0
- Brightline-2: a phase IIa/IIb trial of brigimadlin (BI 907828) in advanced biliary tract cancer, pancreatic ductal adenocarcinoma or other solid tumors.Future Oncol · 202419 citationsRCR 2.2
- 14 citationsRCR 0.5
- Pharmacogenomic characterization of gemcitabine response--a framework for data integration to enable personalized medicine.Pharmacogenet Genomics · 201413 citationsRCR 0.4
- Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial.Cancer Chemother Pharmacol · 2026